Načítá se...
Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
INTRODUCTION: Anti‐vascular endothelial growth factor therapy has been shown to be effective in non‐small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE); however, there are no data to suggest that ramucirumab has the same effects. METHODS: We therefore decided to conduct a p...
Uloženo v:
| Vydáno v: | Thorac Cancer |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons Australia, Ltd
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6996979/ https://ncbi.nlm.nih.gov/pubmed/31851428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13279 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|